Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 years and over)

Document first published:: 9 December 2021
Page updated:: 16 March 2022
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Guidance

Abatacept is recommended to be available as a treatment option through routine commissioning for refractory idiopathic inflammatory myopathies within the criteria set out in these documents. The policy is restricted to patients aged 2 years and over as per the drug’s licence in other indications.

Document

$Clinical commissioning policy: abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Clinical commissioning policy: abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
286 KB
10 pages

Document

$Evidence review: abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Evidence review: abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
416 KB
38 pages

Document

$Equality and health inequalities impact assessment: abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Equality and health inequalities impact assessment: abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
70 KB
10 pages

Document

$Clinical Priorities Advisory Group report: abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Clinical Priorities Advisory Group report: abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
146 KB
8 pages

Document

$Engagement report: abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Engagement report: abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
110 KB
4 pages

Document

$Clinical Panel report (Sep 2020): abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Clinical Panel report (Sep 2020): abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
41 KB
4 pages

Document

$Clinical Panel report (Feb 2021): abatacept for refractory idiopathic inflammatory myopathies (IIM)$

Clinical Panel report (Feb 2021): abatacept for refractory idiopathic inflammatory myopathies (IIM)

PDF
40 KB
4 pages

Cookies on the NHS England website

Clinical commissioning policy: abatacept for refractory idiopathic inflammatory myopathies (IIM)

Evidence review: abatacept for refractory idiopathic inflammatory myopathies (IIM)

Equality and health inequalities impact assessment: abatacept for refractory idiopathic inflammatory myopathies (IIM)

Clinical Priorities Advisory Group report: abatacept for refractory idiopathic inflammatory myopathies (IIM)

Engagement report: abatacept for refractory idiopathic inflammatory myopathies (IIM)

Clinical Panel report (Sep 2020): abatacept for refractory idiopathic inflammatory myopathies (IIM)

Clinical Panel report (Feb 2021): abatacept for refractory idiopathic inflammatory myopathies (IIM)